Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 23, Issue SUPPL. 7, 2012, Pages

  Escudier, B ^a   Eisen, T ^b   Porta, C ^c   Patard, J J ^d   Khoo, V ^e   Algaba, F ^f   Mulders, P ^g   Kataja, V ^h  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b NIHR Cambridge Biomedical Research Centre   (United Kingdom)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d BICÊTRE HOSPITAL   (France)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f FUNDACIÓ PUIGVERT   (Spain)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; EVEROLIMUS; INTERFERON; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADVANCED CANCER; ARTICLE; BONE DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CRYOABLATION; DNA MODIFICATION; DRUG EFFICACY; FOLLOW UP; GENETIC ASSOCIATION; HUMAN; KIDNEY CARCINOMA; LAPAROSCOPIC SURGERY; METASTASIS RESECTION; MOLECULAR PATHOLOGY; NEPHRECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; TREATMENT RESPONSE;

EID: 84866594008     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds227     Document Type: Article

References (23)

1. Rini B, Campbell S, Escudier B. Renal cell carcinoma. Lancet 2009; 373(9669): 1119-1132.
2. Patard JJ, Leray E, Rioux-Leclercq N et al. Prognostic value of histologic subtypes in renal cell carcinomas: a multicenter experience. J Clin Oncol 2005; 23: 2763-2771.
3. Algaba F, Akaza H, Lopez-Beltran A et al. Current pathology keys of renal cell carcinoma. Eur Urol 2011; 60: 634-644.
4. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 1997; 10: 537-544.
5. Argani P, Lal P, Hutchinson B et al. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions. A sensitive and specific immunohistochemical assay. Am J Surg Pathol 2003; 27: 750-761.
6. Leibovich BC, Blute M, Cheville JC et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003; 97: 1663-1671.
7. Patard JJ, Kim HL, Lam JS et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 2004; 22(16): 3316-3322.
8. Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27(34): 5794-5799.
9. MacLennan S, Imamura M, Lapitan MC et al. UCAN Systematic Review Reference Group; EAU Renal Cancer Guideline Panel. Systematic review of oncological outcomes following surgical management of localised renal cancer. Eur Urol 2012; 61(5): 972-793.
10. Best SL, Park SK, Yaacoub RF et al. Long-term outcomes of renal tumor radio frequency ablation stratified by tumor diameter: size matters. J Urol 2012; 187 (4): 1183-1189.
11. Mason RJ, Abdolell M, Trottier G et al. Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance. Eur Urol 2011; 59(5): 863-867.
12. Flanigan RC, Mickisch G, Sylvester R et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004; 171: 1071-1076.
13. Karam JA, Rini BI, Varella L et al. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol 2011; 185(2): 439-444.
14. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
15. Motzer R, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356(2): 115-124.
16. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28(6): 1061-1068.
17. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356(22): 2271-2281.
18. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356(2): 125-134.
19. Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378(9807): 1931-1939.
20. Motzer RJ, Escudier B, Oudard S et al. for the RECORD-1 Study Group. Everolimus for advanced renal cell carcinoma. Lancet 2008; 372(9637): 449-456.
21. Khoo VS, Pyle L. Radiotherapy and supportive care. In Eisen T, Christmas T (eds), Clinical Progress in Renal Cancer. Oxford: Informa UK Ltd 2007; 191-201. ISBN 10-1-84184-604-X.
22. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletalrelated events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003; 98(5): 962-969.
23. Aapro M, Abrahamsson PA, Body JJ et al. Guidance on the use of bisphosphonates in solid tumors: recommendations of an international expert panel. Ann Oncol 2008; 19(3): 420-432.